Department of Epidemiology and Biostatistics, Institute for Human Genetics, and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94158, USA.
Sci Transl Med. 2010 Dec 15;2(62):62ps55. doi: 10.1126/scitranslmed.3001861.
The use of a prostate-specific antigen (PSA) test to screen for prostate cancer is controversial because of its modest predictive value and the potential overdiagnosis and over-treatment of the disease. A research article in this issue of Science Translational Medicine describes single-nucleotide polymorphisms (SNPs) in or near six genes that are independently associated with serum PSA concentrations and that help to explain interindividual PSA variation. Three of these SNPs are also associated with prostate biopsy outcomes. These findings are an important step toward incorporating genetic markers into PSA screening, with the ultimate goal of devising personalized PSA tests for use in the clinic.
使用前列腺特异性抗原（PSA）检测进行前列腺癌筛查存在争议，因为其预测价值有限，且可能导致过度诊断和过度治疗。本期《科学转化医学》中的一篇研究文章描述了六个基因中的或附近的单核苷酸多态性（SNPs），这些 SNPs 与血清 PSA 浓度独立相关，并有助于解释个体间 PSA 变化。这三个 SNPs 也与前列腺活检结果相关。这些发现是将遗传标志物纳入 PSA 筛查的重要一步，最终目标是设计用于临床的个性化 PSA 检测。
